Holger Dorrer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Holger Dorrer has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- A. Türler
Department of Chemistry, Biochemistry and Pharmaceutical Sciences, Faculty of Science, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland
2 shared publications Alexander Hohn
1 shared publication- Cristina Müller
Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
1 shared publication - Josefine Reber
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
1 shared publication - Karl Johnston
CERN
1 shared publication - Konstantin Zhernosekov1 shared publication
Latest Publications
- Open Access
- 13 March 2014
- Published by MDPI AG in Pharmaceuticals
- Vol. 7 (3) , 353-365
Folate Receptor Targeted Alpha-Therapy Using Terbium-149
Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (Eα = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 149Tb-labeled DOTA-folate conjugate (cm09) using folate receptor (FR)-positive cancer cells in vitro and in tumor-bearing mice. 149Tb was produced at the ISOLDE facility at CERN. Radiolabeling of cm09 with purified 149Tb resulted in a specific activity of ~1.2 MBq/nmol. In vitro assays performed with 149Tb-cm09 revealed a reduced KB cell viability in a FR-specific and activity concentration-dependent manner. Tumor-bearing mice were injected with saline only (group A) or with 149Tb-cm09 (group B: 2.2 MBq; group C: 3.0 MBq). A significant tumor growth delay was found in treated animals resulting in an increased average survival time of mice which received 149Tb-cm09 (B: 30.5 d; C: 43 d) compared to untreated controls (A: 21 d). Analysis of blood parameters revealed no signs of acute toxicity to the kidneys or liver in treated mice over the time of investigation. These results demonstrated the potential of folate-based α-radionuclide therapy in tumor-bearing mice.
- 13 March 2014
- Published by MDPI AG in Pharmaceuticals
- Vol. 7 (3) , 353-365
Open AccessFolate Receptor Targeted Alpha-Therapy Using Terbium-149
Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (Eα = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 149Tb-labeled DOTA-folate conjugate (cm09) using folate receptor (FR)-positive cancer cells in vitro and in tumor-bearing mice. 149Tb was produced at the ISOLDE facility at CERN. Radiolabeling of cm09 with purified 149Tb resulted in a specific activity of ~1.2 MBq/nmol. In vitro assays performed with 149Tb-cm09 revealed a reduced KB cell viability in a FR-specific and activity concentration-dependent manner. Tumor-bearing mice were injected with saline only (group A) or with 149Tb-cm09 (group B: 2.2 MBq; group C: 3.0 MBq). A significant tumor growth delay was found in treated animals resulting in an increased average survival time of mice which received 149Tb-cm09 (B: 30.5 d; C: 43 d) compared to untreated controls (A: 21 d). Analysis of blood parameters revealed no signs of acute toxicity to the kidneys or liver in treated mice over the time of investigation. These results demonstrated the potential of folate-based α-radionuclide therapy in tumor-bearing mice.
- 31 August 2010
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 37 (6) , 718-719
The low-energy β− and electron emitter 161Tb as alternative for 177Lu for targeted radionuclides therapy
- 31 August 2010
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 37 (6) , 718-719
The low-energy β− and electron emitter 161Tb as alternative for 177Lu for targeted radionuclides therapy